The LLS Blog
Read about survivors, research, fundraising and advocacy.
FDA Approval of New Treatment Option for Children with Secondary Acute Myeloid Leukemia is a Welcome Step Forward
Here at The Leukemia & Lymphoma Society (LLS), we applaud every advance for children with blood cancers.
FDA Approves Novel Car T-Immunotherapy for the Treatment of Multiple Myeloma
Chimeric Antigen Receptor (CAR) T cell-therapy is on a roll. Today marks the seventh approval of CAR T therapy since the first approval in 2017.
Another First: FDA Approves Car T-Immunotherapy for Treatment of Aggressive Form of Indolent Non-Hodgkin Lymphoma
The U.S. Food and Drug Administration (FDA) today approved the CAR T-cell treatment axicabtagene ciloleucel (Yescarta®) for patients with follicular lymphoma (FL) that has returned or worsened despite earlier treatment. FL is the most common slow-growing non-Hodgkin’s lymphoma and while the disease can generally be managed, reoccurrence is common.
Meet Three Women in Science Championing Myeloma Cures and Care
Annamaria Gulla, MD, Dana-Farber Cancer Institute, is an LLS Career Development Program Fellow. With support from LLS, Dr. Gulla is working to improve outcomes for multiple myeloma patients through the power of immunotherapy. Immunotherapy – harnessing the immune system to fight cancer – has become a mainstay in cancer treatment. One promising approach centers on the evidence that cancer cells dying from specific treatment can be recognized by the patient’s own immune system, triggering an immune response against the disease. Dr. Gulla aims to characterize the molecular mechanisms behind this process – called immunogenic cell death – in multiple myeloma.
Honoring My Daughter’s Legacy By Continuing Her Fight
Today is International Childhood Cancer Day, a day that had little significance for me less than four short years ago. In October 2017, I heard the words, “Your child has cancer,” which I soon learned could only be eclipsed by, “there is nothing more we can do.”